Leishmania mexicana Infection Induces IgG to Parasite Surface Glycoinositol Phospholipids that Can Induce IL-10 in Mice and Humans

PLoS Neglected Tropical Diseases

Volumn 7, Issue 5, 2013, Pages

  Buxbaum, Laurence U ^a,b,c  

^a Philadelphia Research and Education Foundation   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOINOSITOL PHOSPHOLIPID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; LIPOPHOSPHOGLYCAN; MONOCLONAL ANTIBODY; PHOSPHOLIPASE A2; PHOSPHOLIPID DERIVATIVE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOBLOTTING; LEISHMANIASIS; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; THIN LAYER CHROMATOGRAPHY;

EID: 84878506759     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002224     Document Type: Article

References (37)

1. WHO (2005) WHO: Leishmaniasis. Available: http://www.who.int/leishmaniasis/en/. Accessed 30 March 2011.
2. Bryceson AD, Chulay JD, Ho M, Mugambii M, Were JB, et al. (1985) Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies. Trans R Soc Trop Med Hyg 79: 700-704.
3. Sundar S, More DK, Singh MK, Singh VP, Sharma S, et al. (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1107.
4. Soto J, Toledo J, Vega J, Berman J, (2005) Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis. Am J Trop Med Hyg 72: 421-422.
5. Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, et al. (1976) Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 89: 184-194.
6. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, et al. (1980) Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303: 833-841.
7. Hoover DL, Berger M, Nacy CA, Hockmeyer WT, Meltzer MS, (1984) Killing of Leishmania tropica amastigotes by factors in normal human serum. J Immunol 132: 893-897.
8. Mosser DM, Wedgwood JF, Edelson PJ, (1985) Leishmania amastigotes: resistance to complement-mediated lysis is not due to a failure to fix C3. J Immunol 134: 4128-4131.
9. Kima PE, Constant SL, Hannum L, Colmenares M, Lee KS, et al. (2000) Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J Exp Med 191: 1063-1068.
10. Miles SA, Conrad SM, Alves RG, Jeronimo SM, Mosser DM, (2005) A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 201: 747-754.
11. Chu N, Thomas BN, Patel SR, Buxbaum LU, (2010) IgG1 is pathogenic in Leishmania mexicana infection. J Immunol 185: 6939-6946.
12. Soong L, Henard CA, Melby PC, (2012) Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis. Semin Immunopathol 34: 735-751.
13. Jones DE, Buxbaum LU, Scott P, (2000) IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J Immunol 165: 364-372.
14. Buxbaum LU, Scott P, (2005) Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions. Infect Immun 73: 2101-2108.
15. Buxbaum LU, Uzonna JE, Goldschmidt MH, Scott P, (2002) Control of New World cutaneous leishmaniasis is interleukin-12 independent but STAT4 dependent. Eur J Immunol 32: 3206-3215.
16. Thomas BN, Buxbaum LU, (2008) FcgammaRIII mediates immunoglobulin G-induced interleukin-10 and is required for chronic Leishmania mexicana lesions. Infect Immun 76: 623-631.
17. Winter G, Fuchs M, McConville MJ, Stierhof YD, Overath P, (1994) Surface antigens of Leishmania mexicana amastigotes: characterization of glycoinositol phospholipids and a macrophage-derived glycosphingolipid. J Cell Sci 107 (Pt 9) (): 2471-2482.
18. McConville MJ, Homans SW, Thomas-Oates JE, Dell A, Bacic A, (1990) Structures of the glycoinositolphospholipids from Leishmania major. A family of novel galactofuranose-containing glycolipids. J Biol Chem 265: 7385-7394.
19. McConville MJ, Collidge TA, Ferguson MA, Schneider P, (1993) The glycoinositol phospholipids of Leishmania mexicana promastigotes. Evidence for the presence of three distinct pathways of glycolipid biosynthesis. J Biol Chem 268: 15595-15604.
20. McConville MJ, Thomas-Oates JE, Ferguson MA, Homans SW, (1990) Structure of the lipophosphoglycan from Leishmania major. J Biol Chem 265: 19611-19623.
21. Avila JL, Rojas M, Acosta A, (1991) Glycoinositol phospholipids from American Leishmania and Trypanosoma spp: partial characterization of the glycan cores and the human humoral immune response to them. J Clin Microbiol 29: 2305-2312.
22. Rosen G, Londner MV, Sevlever D, Greenblatt CL, (1988) Leishmania major: glycolipid antigens recognized by immune human sera. Mol Biochem Parasitol 27: 93-99.
23. Sutterwala FS, Noel GJ, Clynes R, Mosser DM, (1997) Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med 185: 1977-1985.
24. Yang Z, Mosser DM, Zhang X, (2007) Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages. J Immunol 178: 1077-1085.
25. Sadick MD, Raff HV, (1985) Differences in expression and exposure of promastigote and amastigote membrane molecules in Leishmania tropica. Infect Immun 47: 395-400.
26. Medina-Acosta E, Karess RE, Schwartz H, Russell DG, (1989) The promastigote surface protease (gp63) of Leishmania is expressed but differentially processed and localized in the amastigote stage. Mol Biochem Parasitol 37: 263-273.
27. McConville MJ, Blackwell JM, (1991) Developmental changes in the glycosylated phosphatidylinositols of Leishmania donovani. Characterization of the promastigote and amastigote glycolipids. J Biol Chem 266: 15170-15179.
28. Bethke U, Muthing J, Schauder B, Conradt P, Muhlradt PF, (1986) An improved semi-quantitative enzyme immunostaining procedure for glycosphingolipid antigens on high performance thin layer chromatograms. J Immunol Methods 89: 111-116.
29. Mensa-Wilmot K, Morris JC, al-Qahtani A, Englund PT, (1995) Purification and use of recombinant glycosylphosphatidylinositol-phospholipase C. Methods Enzymol 250: 641-655.
30. Ralton JE, Milne KG, Guther ML, Field RA, Ferguson MA, (1993) The mechanism of inhibition of glycosylphosphatidylinositol anchor biosynthesis in Trypanosoma brucei by mannosamine. J Biol Chem 268: 24183-24189.
31. Buxbaum LU, Raper J, Opperdoes FR, Englund PT, (1994) Myristate exchange. A second glycosyl phosphatidylinositol myristoylation reaction in African trypanosomes. J Biol Chem 269: 30212-30220.
32. Sutterwala FS, Noel GJ, Salgame P, Mosser DM, (1998) Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med 188: 217-222.
33. Whitaker SM, Colmenares M, Pestana KG, McMahon-Pratt D, (2008) Leishmania pifanoi proteoglycolipid complex P8 induces macrophage cytokine production through Toll-like receptor 4. Infect Immun 76: 2149-2156.
34. Pearson RD, De Queiroz Sousa A, Jeronimo SMB (2000) Leishmania Species: Visceral (Kala-Azar), Cutaneous, and Mucosal Leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone. pp. 2831-2845.
35. Lingwood CA, (1996) Aglycone modulation of glycolipid receptor function. Glycoconj J 13: 495-503.
36. Crook SJ, Boggs JM, Vistnes AI, Koshy KM, (1986) Factors affecting surface expression of glycolipids: influence of lipid environment and ceramide composition on antibody recognition of cerebroside sulfate in liposomes. Biochemistry 25: 7488-7494.
37. Stewart RJ, Boggs JM, (1990) Dependence of the surface expression of the glycolipid cerebroside sulfate on its lipid environment: comparison of sphingomyelin and phosphatidylcholine. Biochemistry 29: 3644-3653.